Summary
Transcranial “diagnostic” ultrasound (US) has been shown to accelerate thrombolysis
related to recombinant tissue-type plasminogen activator (rt-PA). In this in vitro study, we evaluated the potential of US to increase clot dissolution mediated by
Abciximab (Abc) compared to rt-PA. The effect of 1.8-MHz pulsed wave (PW) Doppler
US on dissolution of whole venous blood clots (WBC) and platelet-rich clots (PRC)
treated with Abc and rt-PA was investigated in an in vitro model. Clot dissolution was measured by weight loss. Abc-related WBC dissolution
was enhanced by additional US, but the effect was not any more detectable when the
US was attenuated by a human temporal bone (US-tb). In PRC there was no additional
effect of US on the Abc-related clot lysis. Rt-PA-related clot dissolution was increased
by US in WBC and PRC as well, however, US-tb was only effective in WBC. The effect
of insonation on WBC dissolution treated with the combination of Abc plus rt-PA was
lower compared with those treated with rt-PA. In this in vitro experiment, the additional effect of “diagnostic” US in combination with Abc was
only present in WBC and less strong than with rt-PA. The results do not support the
use of Abc for sonothrombolysis targeting both, fibrin-rich and platelet-rich clots.
In contrast, US when combined with rt-PA increases dissolution in both, WBC and PRC
as well.
Keywords
Transcranial Doppler ultrasound - thrombolysis - stroke